Yselty For Uterine Fibroids Edges Closer To Being Obseva’s First Commercial Product

Positive data from a second Phase III trial will support regulatory filings for linzagolix in the US and Europe, but the GnRH agonist is behind two rival drugs: AbbVie's elagolix and Myovant's relugolix.

Numbers on red running track. Start and Finish point of a race track in a stadium
ObsEsva is looking to join a competitive women's health category • Source: Shutterstock

ObsEva SA's Yselty (linzagolix) is positioned, with data announced on 6 July, to be the third gonadotropin-releasing hormone (GnRH) receptor antagonist on the market in the US for the treatment of heavy menstrual bleeding in women with uterine fibroids, but it will be the Swiss biopharma's first commercial product if it successfully clears regulatory approval.

"If approved, linzagolix would be the first commercial product for ObsEva, turning us from a pure development organization to one...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category